Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Healthy Subjects
Interventions
DRUG

Midazolam

Single oral dose of 7.5 mg midazolam (tablet)

DRUG

Selexipag

Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )

Trial Locations (1)

38610

Investigator Site, Gières

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Actelion

INDUSTRY

NCT02791815 - Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects | Biotech Hunter | Biotech Hunter